MARKET

BHC

BHC

Bausch Health Companies Inc
NYSE
8.62
+0.06
+0.70%
After Hours: 8.52 -0.1 -1.16% 18:27 04/25 EDT
OPEN
8.52
PREV CLOSE
8.56
HIGH
8.66
LOW
8.44
VOLUME
2.80M
TURNOVER
0
52 WEEK HIGH
11.46
52 WEEK LOW
5.57
MARKET CAP
3.16B
P/E (TTM)
-5.3131
1D
5D
1M
3M
1Y
5Y
Bausch Health Cos. Inc. Stock Rises Thursday, Outperforms Market
Shares of Bausch Health Cos. Inc. Inched 0.51% higher to C$11.79 on Thursday. The company closed short of its 52-week high of C$15.43. The S&P/TSX Composite Index rose 0.05% to 21,885.38.
MarketWatch · 15h ago
Bausch + Lomb reports positive study results for Blink NutriTears
Bausch + Lomb reports positive study results for Blink NutriTears. The eyecare company plans to launch the product in the US in early Q3. The study met primary endpoints of change in tear production and participant reports of dry eye symptoms. Bausch and Lomb was spun out of BHC in 2022.
Seeking Alpha · 19h ago
Bausch Health Cos. Inc. Stock Rises Wednesday, Outperforms Market
Shares of Bausch Health Cos. Inc. Inched 0.60% higher to C$11.73 on Wednesday. The company closed short of its 52-week high of C$15.43. The S&P/TSX Composite Index fell 0.63% to 21,873.72.
MarketWatch · 1d ago
FDA approves Amneal's generic version of OTC Narcan
FDA approves Amneal Pharmaceuticals’ OTC Naloxone HCl nasal spray, a generic version of the opioid overdose medication OTC Narcan. Narcan is marketed by drugmaker Emergent Biosolutions. Bausch Health filed a patent infringement suit against the company earlier this month.
Seeking Alpha · 1d ago
Bausch Health Cos. Inc. Stock Rises Tuesday, Outperforms Market
Shares of Bausch Health Cos. Inc. Inched 0.69% higher to C$11.66 Tuesday. The company closed short of its 52-week high of C$15.43. The S&P/TSX Composite Index rose 0.64% to 22,011.72.
MarketWatch · 2d ago
Bausch Health Is Maintained at Sector Perform by RBC Capital
Dow Jones · 2d ago
Bausch Health Price Target Cut to $11.00/Share From $12.00 by RBC Capital
Dow Jones · 2d ago
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $11
Benzinga · 2d ago
More
About BHC
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Webull offers Bausch Health Companies Inc stock information, including NYSE: BHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BHC stock methods without spending real money on the virtual paper trading platform.